Joseph Jimenez - Procter Gamble Lead Independent Director
| PG Stock | USD 166.69 0.86 0.51% |
Director
Mr. Joseph S. Jimenez was appointed Director of the Company effective March 1, 2018. Mr. Jimenez is the former Chief Executive Officer of Novartis AG, a position he held from 2010 to 2018. Prior to this role, he held several other senior positions at Novartis from April 2007 to 2010, as well as various leadership roles at H. J. Heinz Company in Europe and North America from 1999 to 2006 and at ConAgra Foods from 1993 to 1998. He was also an Advisor to the Blackstone Group L.P. from 2006 to 2007. Mr. Jimenez was a Director of General Motors since 2015. He was a Director of ColgatePalmolive from 2010 to 2015. Mr. Jimenezs demonstrated track record of International business leadership and the Digital, Technology, and Innovation experience he gained through his role as CEO of Novartis and other roles at a range of Consumer IndustryRetail companies, such as H.J. Heinz and ConAgra, enables him to provide unique perspective to the Board on commercial, innovation, Marketing, and strategic issues. The Board also benefits from Mr. Jimenezs extensive knowledge of the health care industry, particularly as the Company works to acquire and integrate Merck KGaAs Consumer Health Business. since 2021.
| Age | 60 |
| Tenure | 4 years |
| Address | One Procter & Gamble Plaza, Cincinnati, OH, United States, 45202 |
| Phone | 513 983 1100 |
| Web | https://www.pginvestor.com |
Procter Gamble Management Efficiency
The company has Return on Asset (ROA) of 0.1088 % which means that for every $100 of assets, it generated a profit of $0.1088. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.3106 %, which means that it produced $0.3106 on every 100 dollars invested by current stockholders. Procter Gamble's management efficiency ratios could be used to measure how well Procter Gamble manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to 0.14. The current Return On Capital Employed is estimated to decrease to 0.20. At this time, Procter Gamble's Other Assets are most likely to increase significantly in the upcoming years. The Procter Gamble's current Asset Turnover is estimated to increase to 0.98, while Non Current Assets Total are projected to decrease to roughly 66.5 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Laura Cha | Unilever PLC ADR | 71 | |
| Helene Gayle | Colgate Palmolive | 64 | |
| Strive Masiyiwa | Unilever PLC ADR | 60 | |
| Sherilyn McCoy | Kimberly Clark | 62 | |
| Richard Carmona | The Clorox | 71 | |
| Janet Vergis | Church Dwight | 57 | |
| LAURIE YOLER | Church Dwight | 56 | |
| Olivier Goudet | Coty Inc | 56 | |
| Michael Polk | Colgate Palmolive | 60 | |
| Kenneth Mitchell | ELF Beauty | 44 | |
| Vittorio Colao | Unilever PLC ADR | 57 | |
| Esther Lee | The Clorox | 62 | |
| Robert Decherd | Kimberly Clark | 69 | |
| Robert Shearer | Church Dwight | 69 | |
| Christa Quarles | Kimberly Clark | 47 | |
| Wei Christianson | Estee Lauder Companies | 64 | |
| Thomas Lingard | Unilever PLC ADR | N/A | |
| Ian Read | Kimberly Clark | 66 | |
| Stephen Sadove | Colgate Palmolive | 69 | |
| John Rishton | Unilever PLC ADR | 63 | |
| Allan Mackay | The Clorox | 65 | |
Management Performance
| Return On Equity | 0.31 | ||||
| Return On Asset | 0.11 |
Procter Gamble Leadership Team
Elected by the shareholders, the Procter Gamble's board of directors comprises two types of representatives: Procter Gamble inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Procter. The board's role is to monitor Procter Gamble's management team and ensure that shareholders' interests are well served. Procter Gamble's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Procter Gamble's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kathleen Fish, Chief Research, Development and Innovation Officer | ||
| Craig Buchholz, Chief Communications Officer and Vice President – Communications, Personal Health Care and Oral Care | ||
| Matthew Janzaruk, Senior Officer | ||
| Mary FergusonMcHugh, Group President - Global Family Care and Global Brand Creation and Innovation, P&G Ventures | ||
| Debra Lee, Independent Director | ||
| Mindy Sherwood, President Global Walmart | ||
| Amy Chang, Independent Director | ||
| Nelson Peltz, Independent Director | ||
| Magesvaran Suranjan, President - Asia Pacific Selling and Market Operations | ||
| Kirti Singh, Chief Analytics and Insights Officer | ||
| Francis Blake, Independent Director | ||
| Seth Cohen, Chief Officer | ||
| Thomas Finn, President - Personal Health Care | ||
| Alexandra Keith, President - Global Hair Care and Beauty Sector | ||
| Valarie Sheppard, Controller and Treasurer and Executive Vice President - Company Transition Leader | ||
| Fama Francisco, Chief Executive Officer - Baby and Feminine Care | ||
| Loic Tassel, President - Europe | ||
| Margaret Whitman, Independent Director | ||
| Walter McNerney, Lead Independent Director | ||
| Terry Lundgren, Independent Director | ||
| Shelly McNamara, Senior Vice President of Human Resources | ||
| Angela Braly, Independent Director | ||
| Madhusudan Gopalan, Senior Korea | ||
| Loc Tassel, President Europe | ||
| M Grabowski, Chief Human Resource Officer | ||
| Victor Aguilar, Chief Research, Development and Innovation Officer | ||
| Damon Jones, Chief Officer | ||
| Javier Polit, Chief Information Officer | ||
| B Allen, Independent Director | ||
| Steven Bishop, Group President - Global Feminine and Family Care | ||
| Scott Cook, Independent Director | ||
| Henry Karamanoukian, President Go-to-Market, China and Hair Care, Greater China | ||
| Sundar Raman, President - Fabric Care, North America and P&G Professional, Global | ||
| Susan Whaley, Chief Secretary | ||
| R Keith, President - Global Hair Care and Beauty Sector | ||
| Ma Francisco, Chief Executive Officer - Baby and Feminine Care | ||
| Jennifer Davis, President - Feminine Care | ||
| John Chevalier, Director - Investor Relations | ||
| Juan Posada, President - Latin America Selling and Market Operations | ||
| Fatima Francisco, Feminine Baby | ||
| Monica Turner, Senior Vice President - Sales, North America | ||
| Vittorio Cretella, Chief Information Officer | ||
| Christine McCarthy, Independent Director | ||
| Patricia Woertz, Independent Director | ||
| Shailesh Jejurikar, Chief Operating Officer, Chief Executive Officer - Fabric and Home Care | ||
| Philip Duncan, Chief Design Officer | ||
| Andre Schulten, Chief Financial Officer | ||
| Marc Pritchard, Global Brand Building Officer | ||
| Markus Strobel, President - Skin & Personal Care | ||
| David Taylor, Chairman of the Board, President, Chief Executive Officer | ||
| Joseph Jimenez, Lead Independent Director | ||
| Matthew Price, President - Greater China Selling and Market Operations | ||
| Julio Nemeth, President - Global Business Services | ||
| Laura Becker, President - Global Business Services | ||
| Deborah Majoras, Chief Legal Officer, Secretary | ||
| Jon Moeller, Vice Chairman of the Board, President, Chief Executive Officer | ||
| Gary Coombe, President - Europe Selling and Market Operations | ||
| Carolyn Tastad, Group President - North America Selling and Market Operations | ||
| Ken Patel, Chief Counsel |
Procter Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Procter Gamble a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.31 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 418.12 B | ||||
| Shares Outstanding | 2.34 B | ||||
| Shares Owned By Insiders | 0.05 % | ||||
| Shares Owned By Institutions | 69.76 % | ||||
| Number Of Shares Shorted | 18.11 M | ||||
| Price To Earning | 25.21 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Procter Gamble. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more detail on how to invest in Procter Stock please use our How to Invest in Procter Gamble guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Household Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Procter Gamble. If investors know Procter will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Procter Gamble listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.341 | Dividend Share 3.96 | Earnings Share 6.29 | Revenue Per Share | Quarterly Revenue Growth 0.021 |
The market value of Procter Gamble is measured differently than its book value, which is the value of Procter that is recorded on the company's balance sheet. Investors also form their own opinion of Procter Gamble's value that differs from its market value or its book value, called intrinsic value, which is Procter Gamble's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Procter Gamble's market value can be influenced by many factors that don't directly affect Procter Gamble's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Procter Gamble's value and its price as these two are different measures arrived at by different means. Investors typically determine if Procter Gamble is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Procter Gamble's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.